GFAP and myeloid sarcoma: Currently, several soluble biomarkers have been investigated to detect PIRA in MS, especially neurofilament light chain (NfL), a biomarker of neuroaxonal destruction (6–8), and glial fibrillary acidic protein (GFAP), a biomarker of glial activation (9).